Join to View Full Profile
11100 Euclid AveCleveland, OH 44106
Phone+1 216-844-8500
Fax+1 216-986-0596
Are you Dr. Markowitz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sanford Markowitz, MD is an oncologist in Cleveland, Ohio. He is currently licensed to practice medicine in Ohio and Illinois. He is a Professor of Medicine at Case West Res University.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
University of ChicagoResidency, Internal Medicine, 1981 - 1984
Yale School of MedicineClass of 1980
Certifications & Licensure
OH State Medical License 1987 - 2026
IL State Medical License 1982 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsMulticenter, Prospective Trial of Nonendoscopic Biomarker-Driven Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.Helen R Moinova, Suman Verma, John Dumot, Ashley Faulx, Prasad G Iyer
The American Journal of Gastroenterology. 2024-11-01 - 1 citationsPatients With Esophageal Adenocarcinoma With Prior Gastroesophageal Reflux Disease Symptoms Are Similar to Those Without Gastroesophageal Reflux Disease: A Cross-Secti...Apoorva Krishna Chandar, Komal Keerthy, Rajesh Gupta, William M Grady, Marcia Irene Canto
The American Journal of Gastroenterology. 2024-05-01 - 4 citationsFine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes.Zhishan Chen, Xingyi Guo, Ran Tao, Jeroen R Huyghe, Philip J Law
Nature Communications. 2024-04-26
Press Mentions
Former UK Innovator Contributed to CWRU Biotech Startup Rodeo Therapeutics Acquired by Amgen IncJune 10th, 2021- A Device to Detect Barrett’s Oesophagus and Prevent Oesophageal CancerSeptember 22nd, 2020
Swallowable Device to Detect Barrett's Esophagus Receives FDA 510(K) ClearanceSeptember 5th, 2019- Join now to see all
Grant Support
- A Clinical Trial of Cancer Prevention by Biomarker Based Detections of Barrett's Esophagus and Its ProgressionCASE WESTERN RESERVE UNIVERSITY2025–2029
- Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablationCASE WESTERN RESERVE UNIVERSITY2022–2027
- Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and RegenerationUT SOUTHWESTERN MEDICAL CENTER2021–2026
- Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and RegenerationUT SOUTHWESTERN MEDICAL CENTER2021–2026
